Regulatory News:
MaaT Pharma (EURONEXT: MAAT the "Company"), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to enhancing survival for patients with cancer, today announces its half-year report on the liquidity contract with the firm Kepler Cheuvreux and an increase of €50,000 to the resources allocated to the contract, in accordance with the provisions of article 4 of AMF decision no. 2021-01 of June 22, 2021.
Under the liquidity contract entered into between Maat Pharma and Kepler Cheuvreux, the following resources appeared on the liquidity account on June 30th, 2024:
- 26,929 shares
- 17,089.40
- Number of executions on buy side on semester: 933
- Number of executions on sell side on semester: 1,014
- Traded volume on buy side on semester: 28,959 shares for 237,891.32
- Traded volume on sell side on semester: 26,266 shares for 220,168.07
As a reminder:
- the following resources appeared on the last half year statement on December 31, 2023 on the liquidity account:
- 24,236 shares
- 34,107.60
- Number of executions on buy side on semester: 627
- Number of executions on sell side on semester: 368
- Traded volume on buy side on semester: 18,328 shares for 122,340.49
- Traded volume on sell side on semester: 9,576 shares for 64,693.03
- the following resources appeared on the liquidity account when the activity started:
- 0 shares
- 200,000.00
Following the addition of these resources for the amount of €50,000, the position on July 4th, 2024, is:
- 26,006 shares
- 74,303.08
The implementation of this report is carried out in accordance with AMF Decision N°2021-01 of June 22nd, 2021, renewing the implementation of liquidity contracts for shares as an accepted market practice.
| Buy Side | Sell Side | ||||||
| Number of executions | Number of shares | Traded volume in EUR | Number of executions | Number of shares | Traded volume in EUR | ||
| Total | 933 | 28,959 | 237,891.32 | 1,014 | 26,266 | 220,168.07 | |
| 02/01/2024 | 9 | 102 | 719.10 | ||||
| 03/01/2024 | 3 | 60 | 448.80 | 15 | 435 | 3,275.55 | |
| 04/01/2024 | 9 | 126 | 948.78 | 8 | 211 | 1,612.04 | |
| 05/01/2024 | 2 | 45 | 339.30 | 3 | 90 | 689.40 | |
| 08/01/2024 | 18 | 410 | 2,886.40 | ||||
| 09/01/2024 | 11 | 340 | 2,237.20 | 15 | 425 | 2,843.25 | |
| 10/01/2024 | 5 | 130 | 877.50 | 2 | 72 | 487.44 | |
| 11/01/2024 | 2 | 2 | 13.74 | 10 | 241 | 1,679.77 | |
| 12/01/2024 | 4 | 50 | 351.00 | 2 | 70 | 501.20 | |
| 15/01/2024 | 8 | 203 | 1,408.82 | 8 | 110 | 779.90 | |
| 16/01/2024 | 3 | 36 | 252.00 | 3 | 35 | 246.40 | |
| 17/01/2024 | 5 | 70 | 482.30 | ||||
| 18/01/2024 | 5 | 151 | 1,026.80 | ||||
| 19/01/2024 | 10 | 222 | 1,469.64 | 1 | 30 | 201.00 | |
| 22/01/2024 | 3 | 50 | 351.00 | 27 | 641 | 4,512.64 | |
| 23/01/2024 | 5 | 93 | 672.39 | ||||
| 24/01/2024 | 7 | 175 | 1,242.50 | 4 | 130 | 928.20 | |
| 25/01/2024 | 5 | 71 | 506.94 | 2 | 36 | 257.76 | |
| 26/01/2024 | 3 | 10 | 71.50 | 4 | 93 | 668.67 | |
| 29/01/2024 | 7 | 141 | 1,022.25 | 8 | 155 | 1,148.55 | |
| 30/01/2024 | 2 | 21 | 151.20 | 2 | 36 | 260.64 | |
| 31/01/2024 | 4 | 110 | 784.30 | 6 | 148 | 1,061.16 | |
| 01/02/2024 | 3 | 60 | 430.80 | 2 | 42 | 304.50 | |
| 02/02/2024 | 8 | 160 | 1,142.40 | 8 | 150 | 1,087.50 | |
| 05/02/2024 | 2 | 35 | 250.95 | ||||
| 06/02/2024 | 3 | 70 | 497.00 | 5 | 105 | 753.90 | |
| 07/02/2024 | 4 | 85 | 606.05 | ||||
| 08/02/2024 | 2 | 21 | 149.94 | 5 | 83 | 593.45 | |
| 09/02/2024 | 10 | 185 | 1,311.65 | 6 | 118 | 859.04 | |
| 12/02/2024 | 7 | 127 | 896.62 | 1 | 1 | 7.22 | |
| 13/02/2024 | 1 | 1 | 7.02 | 4 | 24 | 169.44 | |
| 14/02/2024 | 4 | 69 | 481.62 | 2 | 32 | 227.20 | |
| 15/02/2024 | 3 | 26 | 182.52 | 10 | 151 | 1,069.08 | |
| 16/02/2024 | 2 | 30 | 213.00 | 3 | 41 | 293.15 | |
| 19/02/2024 | 7 | 130 | 928.20 | 17 | 280 | 2,027.20 | |
| 20/02/2024 | 15 | 329 | 2,470.79 | ||||
| 21/02/2024 | 9 | 130 | 964.60 | ||||
| 22/02/2024 | 9 | 115 | 865.95 | ||||
| 23/02/2024 | 1 | 1 | 7.62 | 53 | 1,131 | 9,398.61 | |
| 26/02/2024 | 26 | 550 | 4,526.50 | 9 | 103 | 850.78 | |
| 27/02/2024 | 6 | 75 | 612.00 | 13 | 277 | 2,310.18 | |
| 28/02/2024 | 45 | 880 | 6,758.40 | 23 | 706 | 5,655.06 | |
| 29/02/2024 | 15 | 211 | 1,673.23 | 3 | 34 | 270.30 | |
| 01/03/2024 | 4 | 90 | 711.00 | 10 | 200 | 1,606.00 | |
| 04/03/2024 | 14 | 260 | 2,048.80 | 7 | 130 | 1,036.10 | |
| 05/03/2024 | 9 | 162 | 1,263.60 | 10 | 133 | 1,046.71 | |
| 06/03/2024 | 11 | 245 | 2,035.95 | 53 | 1,009 | 8,465.51 | |
| 07/03/2024 | 2 | 20 | 170.40 | 21 | 260 | 2,236.00 | |
| 08/03/2024 | 17 | 335 | 2,814.00 | 6 | 94 | 797.12 | |
| 11/03/2024 | 7 | 114 | 992.94 | 22 | 381 | 3,341.37 | |
| 12/03/2024 | 7 | 139 | 1,234.32 | 10 | 316 | 2,837.68 | |
| 13/03/2024 | 1 | 35 | 315.00 | 25 | 1,039 | 9,735.43 | |
| 14/03/2024 | 30 | 921 | 8,427.15 | 13 | 319 | 2,992.22 | |
| 15/03/2024 | 11 | 291 | 2,697.57 | 28 | 632 | 5,890.24 | |
| 18/03/2024 | 5 | 99 | 903.87 | 3 | 45 | 413.55 | |
| 19/03/2024 | 6 | 74 | 682.28 | ||||
| 20/03/2024 | 20 | 553 | 4,943.82 | 13 | 328 | 2,971.68 | |
| 21/03/2024 | 8 | 370 | 3,204.20 | 3 | 55 | 480.70 | |
| 22/03/2024 | 6 | 125 | 1,113.75 | 19 | 422 | 3,798.00 | |
| 25/03/2024 | 12 | 193 | 1,796.83 | 16 | 481 | 4,540.64 | |
| 26/03/2024 | 6 | 158 | 1,448.86 | 8 | 173 | 1,600.25 | |
| 27/03/2024 | 1 | 50 | 465.00 | 6 | 258 | 2,414.88 | |
| 28/03/2024 | 22 | 692 | 6,304.12 | 8 | 343 | 3,217.34 | |
| 02/04/2024 | 5 | 185 | 1,626.15 | 6 | 185 | 1,635.40 | |
| 03/04/2024 | 4 | 56 | 495.60 | 1 | 1 | 8.86 | |
| 04/04/2024 | 4 | 90 | 808.20 | ||||
| 05/04/2024 | 17 | 435 | 4,023.75 | ||||
| 08/04/2024 | 9 | 256 | 2,403.84 | 26 | 626 | 5,959.52 | |
| 09/04/2024 | 8 | 133 | 1,263.50 | 10 | 444 | 4,253.52 | |
| 10/04/2024 | 7 | 226 | 2,171.86 | ||||
| 11/04/2024 | 2 | 36 | 342.00 | 5 | 33 | 316.47 | |
| 12/04/2024 | 2 | 20 | 189.60 | 1 | 1 | 9.56 | |
| 15/04/2024 | 41 | 1,314 | 12,246.48 | 25 | 785 | 7,622.35 | |
| 16/04/2024 | 4 | 125 | 1,140.00 | 14 | 325 | 2,996.50 | |
| 17/04/2024 | 13 | 578 | 5,138.42 | ||||
| 18/04/2024 | 3 | 101 | 906.98 | 5 | 266 | 2,420.60 | |
| 19/04/2024 | 21 | 1,779 | 15,726.36 | 7 | 304 | 2,723.84 | |
| 22/04/2024 | 4 | 330 | 2,864.40 | 11 | 593 | 5,200.61 | |
| 23/04/2024 | 3 | 124 | 1,088.72 | 6 | 157 | 1,389.45 | |
| 24/04/2024 | 6 | 217 | 1,907.43 | 2 | 2 | 17.62 | |
| 25/04/2024 | 1 | 1 | 8.80 | 12 | 468 | 4,165.20 | |
| 26/04/2024 | 2 | 130 | 1,170.00 | 3 | 29 | 262.74 | |
| 29/04/2024 | 6 | 285 | 2,676.15 | 20 | 652 | 6,109.24 | |
| 30/04/2024 | 6 | 354 | 3,313.44 | 3 | 105 | 996.45 | |
| 02/05/2024 | 5 | 221 | 2,048.67 | 2 | 80 | 747.20 | |
| 03/05/2024 | 1 | 1 | 9.24 | 7 | 264 | 2,460.48 | |
| 06/05/2024 | 10 | 323 | 3,007.13 | 4 | 91 | 849.94 | |
| 07/05/2024 | 4 | 244 | 2,286.28 | 12 | 466 | 4,385.06 | |
| 08/05/2024 | 1 | 20 | 188.00 | 1 | 5 | 47.30 | |
| 09/05/2024 | 1 | 95 | 898.70 | ||||
| 10/05/2024 | 6 | 161 | 1,513.40 | 2 | 39 | 368.94 | |
| 13/05/2024 | 2 | 103 | 968.20 | 2 | 101 | 952.43 | |
| 14/05/2024 | 2 | 77 | 719.18 | 2 | 84 | 788.76 | |
| 15/05/2024 | 55 | 3,305 | 27,695.90 | 5 | 150 | 1,281.00 | |
| 16/05/2024 | 7 | 340 | 2,692.80 | 9 | 260 | 2,072.20 | |
| 17/05/2024 | 12 | 387 | 3,154.05 | 15 | 325 | 2,668.25 | |
| 20/05/2024 | 8 | 325 | 2,665.00 | 7 | 205 | 1,693.30 | |
| 21/05/2024 | 7 | 265 | 2,130.60 | 4 | 200 | 1,624.00 | |
| 22/05/2024 | 11 | 344 | 2,752.00 | 3 | 88 | 719.84 | |
| 23/05/2024 | 3 | 62 | 494.76 | 6 | 130 | 1,040.00 | |
| 24/05/2024 | 6 | 308 | 2,439.36 | 8 | 230 | 1,826.20 | |
| 27/05/2024 | 1 | 15 | 119.10 | 2 | 80 | 640.80 | |
| 28/05/2024 | 2 | 70 | 558.60 | 3 | 55 | 443.30 | |
| 29/05/2024 | 8 | 212 | 1,704.48 | 5 | 129 | 1,046.19 | |
| 30/05/2024 | 8 | 313 | 2,500.87 | 4 | 88 | 709.28 | |
| 31/05/2024 | 8 | 451 | 3,598.98 | 1 | 1 | 8.04 | |
| 03/06/2024 | 3 | 150 | 1,194.00 | 3 | 50 | 400.00 | |
| 04/06/2024 | 6 | 200 | 1,586.00 | 4 | 110 | 875.60 | |
| 05/06/2024 | 5 | 119 | 940.10 | 5 | 100 | 794.00 | |
| 06/06/2024 | 7 | 250 | 1,970.00 | 1 | 1 | 7.94 | |
| 07/06/2024 | 6 | 214 | 1,697.02 | 8 | 140 | 1,113.00 | |
| 10/06/2024 | 9 | 305 | 2,400.35 | 1 | 40 | 316.80 | |
| 11/06/2024 | 5 | 200 | 1,560.00 | 5 | 212 | 1,670.56 | |
| 12/06/2024 | 3 | 105 | 807.45 | 1 | 50 | 385.00 | |
| 13/06/2024 | 5 | 163 | 1,253.47 | 4 | 125 | 965.00 | |
| 14/06/2024 | 17 | 440 | 3,291.20 | 2 | 57 | 434.91 | |
| 17/06/2024 | 26 | 700 | 4,704.00 | 6 | 285 | 1,915.20 | |
| 18/06/2024 | 3 | 60 | 403.80 | 7 | 355 | 2,410.45 | |
| 19/06/2024 | 10 | 591 | 3,953.79 | 3 | 39 | 267.54 | |
| 20/06/2024 | 4 | 68 | 450.84 | 7 | 150 | 1,009.50 | |
| 21/06/2024 | 2 | 51 | 346.80 | 5 | 303 | 2,084.64 | |
| 24/06/2024 | 1 | 19 | 131.10 | 7 | 174 | 1,211.04 | |
| 25/06/2024 | 7 | 150 | 1,081.50 | 10 | 360 | 2,610.00 | |
| 26/06/2024 | 26 | 944 | 7,174.40 | ||||
| 27/06/2024 | 19 | 613 | 4,677.19 | 4 | 89 | 688.86 | |
| 28/06/2024 | 23 | 904 | 6,535.92 | 4 | 187 | 1,357.62 | |
About MaaT Pharma
MaaT Pharma, a clinical stage biotechnology company, has established a complete approach to restoring patient-microbiome symbiosis in oncology. Committed to treating cancer and graft-versus-host disease (GvHD), a serious complication of allogeneic stem cell transplantation, MaaT Pharma has launched, in March 2022, an open-label, single arm Phase 3 clinical trial in patients with acute GvHD, following the achievement of its proof of concept in a Phase 2 trial. Its powerful discovery and analysis platform, gutPrint, enables the identification of novel disease targets, evaluation of drug candidates, and identification of biomarkers for microbiome-related conditions. The company's Microbiome Ecosystem Therapies are produced through a standardized cGMP manufacturing and quality control process to safely deliver the full diversity of the microbiome, in liquid and oral formulations. MaaT Pharma benefits from the commitment of world-leading scientists and established relationships with regulators to support the integration of the use of microbiome therapies in clinical practice. MaaT Pharma is listed on Euronext Paris (ticker: MAAT).
View source version on businesswire.com: https://www.businesswire.com/news/home/20240705981889/en/
Contacts:
MaaT Pharma Investor Relations
Guilhaume DEBROAS, Ph.D.
Head of Investor Relations
+33 6 16 48 92 50
invest@maat-pharma.com
MaaT Pharma Media Relations
Pauline RICHAUD
Senior PR Corporate Communications Manager
+33 6 14 06 45 92
media@maat-pharma.com
Trophic Communications
Jacob VERGHESE or
Desmond JAMES
+49 151 7441 6179
maat@trophic.eu
